Related Experiment Video
Updated: Apr 6, 2026

Assembly and Purification of Prototype Foamy Virus Intasomes
Published on: March 19, 2018
Interfacial inhibitors
Yves Pommier1, Evgeny Kiselev1, Christophe Marchand1
1Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, United States.
Abstract:
Targeting macromolecular interface is a general mechanism by which natural products inactivate macromolecular complexes by stabilizing normally transient intermediates. Demonstrating interfacial inhibition mechanism ultimately relies on the resolution of drug-macromolecule structures. This review focuses on medicinal drugs that trap protein-DNA complexes by binding at protein-DNA interfaces. It provides proof-of-concept and detailed structural and mechanistic examples for topoisomerase inhibitors and HIV integrase inhibitors. Additional examples of recent interfacial inhibitors for protein-DNA interfaces are provided, as well as prospects for targeting previously 'undruggable' targets including transcription, replication and chromatin remodeling complexes. References and discussion are included for interfacial inhibitors of protein-protein interfaces.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Dipeptidyl Peptidase 4 Inhibitors
Interfacial Electrochemical Methods: Overview
Enzyme Inhibition
Theories of Dissolution: The Danckwerts' Model and Interfacial Barrier Model
Protein-Protein Interfaces

